Abstract
Ethical questions surrounding the administration of synthetic growth hormone (GH) to short normal children can be grouped into the following four categories: 1) appropriateness of medical treatment when no disease or biological deficiency is present; 2) how to proceed in the face of ambiguity or uncertainty of research results; 3) difficulty in weighing the risks and benefits of treatment; and 4) who should decide? This article seeks to determine whether GH administration to normal short children is properly considered an 'enhancement', and, if so, whether such treatment would be ethically wrong.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of pediatric endocrinology & metabolism : JPEM
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
